Table 2 Effects of DMAB modification on size, entrapment efficiency and zeta potential
From: Oral Delivery of DMAB-Modified Docetaxel-Loaded PLGA-TPGS Nanoparticles for Cancer Chemotherapy
Group | Polymer | Size (nm) | PDI | Zeta Potential (mV) | Drug loading (%) | EE (%) | DMAB Modification (%) |
|---|---|---|---|---|---|---|---|
ANP | PLGA | 239.82 ± 8.64 | 0.299 | -28.58 ± 4.44 | 8.93 | 88.26 | 5 |
BNP | PLGA-TPGS | 253.51 ± 5.38 | 0.264 | -21.87 ± 2.11 | 9.83 | 98.27 | None |
CNP | PLGA-TPGS | 226.33 ± 3.56 | 0.251 | 32.23 ± 3.55 | 9.62 | 96.23 | 5 |
DNP | PLGA-TPGS | 219.42 ± 5.24 | 0.199 | 34.15 ± 4.28 | 9.21 | 92.12 | 20 |